Search

Objective: A myelodysplastic syndrome (MDS) is a heterogeneous group of diseases characterized by abnormal cellular proliferation in the bone marrow, cytopenia in one or more cell lines in the peripheral blood, dysplasia in the bone marrow, and risk of developing acute myeloid leukemia (AML).This study aims to evaluate demographic data, conventional cytogenetics, Fluorescent in situ hybridization (FISH), and prognostic features in MDS patients. Methods: Patients aged 18 years and over 18 years of age with MDS who were followed up in the DEUTF Hematology Department between January 2010 and January 2020 were included in this study. The data of the patients were searched retrospectively. Hemogram, biochemistry, cytogenetic and FISH results, survival, treatments, cytopenia grades, bone marrow blast percentages, bone marrow biopsy results of patients diagnosed at any time were examined. Results: A total of 205 patients over the age of 18 diagnosed with MDS and followed up between January 2010 and January 2020 were included in the study. The female/male ratio was found to be 0.8/1. The median was 70.7 (27-92). The median hemoglobin value was 9.4 g/dl (4.8-14.5). MDS cases are classified according to the 2016 Revised-WHO Classification; it was detected in the MDS-SLD group with the highest 78 patients (38%). A normal karyotype was found in 112 (79.4%) of 141 patients for whom conventional cytogenetic analysis could be performed, and the most common cytogenetic anomaly detected with this method was complex karyotype (n=9, 6.3%). The median survival of 135 patients with the FISH panel was evaluated according to their genetic anomalies. According to the FISH result, in the patient populations with 7q deletion and P53 mutation, decreased median survival times were statistically significant compared to the group without mutation (p-value <0.05). It was determined that survival decreased significantly as the percentage of CD34 increased in the bone marrow. When the median survival of the patients was evaluated according to the IPSS stage, the median survival of the patients in the advanced stage was statistically significantly lower. Conclusion: Studies on the genetic basis of myelodysplastic syndrome play an essential role in shaping the diagnosis, staging, prognosis, and treatment methods of the disease. [ABSTRACT FROM AUTHOR]

Aim:Retrospective, cross-sectional, observational study to examine the frequency and features of paroxysmal nocturnal hemoglobinuria (PNH) clones in patients with myelodysplastic syndrome (MDS).Methods:Data were analyzed from the medical files of 41 MDS patients diagnosed and followed up in the hematology department at a referral center between 2006 and 2017. Descriptive data, cytogenetic and hematologic characteristics, prognostic features and PNH clone sizes were assessed. PNH clone sizes were evaluated using the fluorescently labeled inactive toxin aerolysin method.Results:The study population comprised 22 (53.7%) female and 19 (46.3%) male patients with confirmed MDS; the mean age of the patients was 68.20±9.84 years (range, 45-85). PNH clones were detected in eight (19.5%) patients. The number of patients with a PNH clone size of >10%, >1%, >0.1% and >0.01% was one, one, one and eigth, respectively (p

Copyright of Journal of Ankara University Faculty of Medicine / Ankara Üniversitesi Tip Fakültesi Mecmuasi is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Behçet's disease (BD) is a systemic vasculitis, while myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematologic disorders characterized by ineffective hematopoiesis. Some studies suggest a relationship between MDS and BD, especially intestinal BD, and trisomy 8 seems to play an important role in both diseases. The presence of trisomy 8 is thought to be related to the intestinal involvement of BD. Here, we presented a case with the coexistence of intestinal BD, MDS, and trisomy 8. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Ankara University Faculty of Medicine / Ankara Üniversitesi Tip Fakültesi Mecmuasi is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The myelodysplastic syndrome (MDS) is a clonal stem cell disorder characterized by ineffective blood cell production and dysplasia. The most important clinical findings are anemia, leucopenia and trombocytopenia or their combinations. The MDS patients could have chronic asymptomatic cytopenias or symptomatic anemia, infections and bleeding disorders and there is a variable risk of transformation to acute leukemia. It is generally an elderly disease and though, its' etiology is unknown most of the time; chemotherapy and radiotherapy may exert a mutant effect on the stem cells. The incidence of MDS with unknown etiology is 4/100000 and this ratio exceeds that of acute myeloid leukemia. [ABSTRACT FROM AUTHOR]

Myelodysplastic syndrome is a group of stem cell disorder that is characterized by ineffective hematopoiesis and transformation to acute leukemia. Genetic analyses have an important role in establishing the diagnosis and determining the appropriate chemotherapy. Here a patient with myelodysplastic syndrome in whom isochromosome of long arm of chromosome 17 [i (17q)] cytogenetic abnormality was detected is presented and clinical findings in patients with this anomaly are discussed. Although i(17q) cytogenetic abnormality is a very rarely seen genetic change in patients with myelodysplastic syndrome, it is accepted as a poor prognostic criterion according to literature findings. Thus patients of myelodysplastic syndrom with this cytogenetic abnormality may be considered as a different clinical syndrome during the follow-up and treatment. [ABSTRACT FROM AUTHOR]